Efficacy and safety of gut microbiome-targeted treatment in patients with depression: a systematic review and meta-analysis
Abstract Background The study aimed to comprehensively analyze and establish a framework for evaluating the efficacy of microbiome–targeted treatment (MTT) for depression. Methods We searched PubMed, Embase, Cochrane Library, Web of Science, and the Chinese National Knowledge Infrastructure database...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12888-024-06438-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585521064312832 |
|---|---|
| author | Bo Pan Yiming Pan Yu-Song Huang Meng Yi Yuwei Hu Xiaoyu Lian Hui-Zhong Shi Mingwei Wang Guifen Xiang Wen-Yi Yang Zhong Liu Fangfang Xia |
| author_facet | Bo Pan Yiming Pan Yu-Song Huang Meng Yi Yuwei Hu Xiaoyu Lian Hui-Zhong Shi Mingwei Wang Guifen Xiang Wen-Yi Yang Zhong Liu Fangfang Xia |
| author_sort | Bo Pan |
| collection | DOAJ |
| description | Abstract Background The study aimed to comprehensively analyze and establish a framework for evaluating the efficacy of microbiome–targeted treatment (MTT) for depression. Methods We searched PubMed, Embase, Cochrane Library, Web of Science, and the Chinese National Knowledge Infrastructure database for randomized controlled trials (RCTs) on MTT in treating depression until October 19, 2023. A meta-analysis was conducted to evaluate the efficacy and safety of MTT. Comprehensive subgroup analyses were undertaken to explore factors influencing MTT’s efficacy in treating depression. This study was registered with PROSPERO (CRD42023483649). Results The study selection process identified 51,570 studies, of which 34 met the inclusion criteria. The overall pooled estimates showed that MTT significantly improved depression symptoms (SMD −0.26, 95% CI [−0.32, −0.19], I 2 = 54%) with acceptable safety. Subgroup analyses by geography showed that effectiveness was demonstrated in Asia (SMD −0.46, 95% CI [−0.56, −0.36], I 2 = 36%), while no evidence of effectiveness was found in Europe (SMD −0.07, 95% CI [−0.19, 0.05], I 2 = 55%), America (SMD −0.33, 95% CI [−0.67, 0.02], I 2 = 60%), and Oceania (SMD 0.00, 95% CI [−0.18, 0.18], I 2 = 0%). Besides, the efficacy was shown in depressed patients without comorbidities (SMD −0.31, 95% CI [−0.40, −0.22], I 2 = 0%), whereas effectiveness was poor in those with digestive disorders, such as irritable bowel syndrome (SMD −0.37, 95% CI [−0.89, 0.16], I 2 = 74%), chronic diarrhea (SMD −0.34, 95% CI [−0.73, 0.05]), and chronic constipation (SMD −0.23, 95% CI [−0.57, 0.11], I 2 = 0%). In perinatal depressed patients, MTT was not effective (SMD 0.16, 95% CI [0.01, 0.31], I 2 = 0%). It was found that < 8 weeks (SMD −0.33, 95% CI [−0.45, −0.22], I 2 = 0%) and 8–12 weeks (SMD −0.34, 95% CI [−0.44, −0.23], I 2 = 57%) MTT were effective, while > 12 weeks (SMD 0.02, 95% CI [−0.12, 0.17], I 2 = 68%) MTT was ineffective. Conclusions Despite the overall effectiveness of MTT in treating depression and its acceptable safety profile, caution is warranted in drawing this conclusion due to limitations posed by the small sample size of included studies and heterogeneity. The efficacy of MTT for depression exhibits variation influenced by geography, patient comorbidities, and duration of administration. |
| format | Article |
| id | doaj-art-bfb6129cb7864ed3bda1afb80e60c88b |
| institution | Kabale University |
| issn | 1471-244X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Psychiatry |
| spelling | doaj-art-bfb6129cb7864ed3bda1afb80e60c88b2025-01-26T12:46:51ZengBMCBMC Psychiatry1471-244X2025-01-0125111610.1186/s12888-024-06438-zEfficacy and safety of gut microbiome-targeted treatment in patients with depression: a systematic review and meta-analysisBo Pan0Yiming Pan1Yu-Song Huang2Meng Yi3Yuwei Hu4Xiaoyu Lian5Hui-Zhong Shi6Mingwei Wang7Guifen Xiang8Wen-Yi Yang9Zhong Liu10Fangfang Xia11Institute of Blood Transfusion Institution, Chinese Academy of Medical Sciences and Peking Union Medical CollegeInstitute of Blood Transfusion Institution, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineInstitute of Blood Transfusion Institution, Chinese Academy of Medical Sciences and Peking Union Medical CollegeInstitute of Blood Transfusion Institution, Chinese Academy of Medical Sciences and Peking Union Medical CollegeInstitute of Blood Transfusion Institution, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineInstitute of Blood Transfusion Institution, Chinese Academy of Medical Sciences and Peking Union Medical CollegeInstitute of Blood Transfusion Institution, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineInstitute of Blood Transfusion Institution, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Anesthesiology, the First Affiliated Hospital of Wenzhou Medical UniversityAbstract Background The study aimed to comprehensively analyze and establish a framework for evaluating the efficacy of microbiome–targeted treatment (MTT) for depression. Methods We searched PubMed, Embase, Cochrane Library, Web of Science, and the Chinese National Knowledge Infrastructure database for randomized controlled trials (RCTs) on MTT in treating depression until October 19, 2023. A meta-analysis was conducted to evaluate the efficacy and safety of MTT. Comprehensive subgroup analyses were undertaken to explore factors influencing MTT’s efficacy in treating depression. This study was registered with PROSPERO (CRD42023483649). Results The study selection process identified 51,570 studies, of which 34 met the inclusion criteria. The overall pooled estimates showed that MTT significantly improved depression symptoms (SMD −0.26, 95% CI [−0.32, −0.19], I 2 = 54%) with acceptable safety. Subgroup analyses by geography showed that effectiveness was demonstrated in Asia (SMD −0.46, 95% CI [−0.56, −0.36], I 2 = 36%), while no evidence of effectiveness was found in Europe (SMD −0.07, 95% CI [−0.19, 0.05], I 2 = 55%), America (SMD −0.33, 95% CI [−0.67, 0.02], I 2 = 60%), and Oceania (SMD 0.00, 95% CI [−0.18, 0.18], I 2 = 0%). Besides, the efficacy was shown in depressed patients without comorbidities (SMD −0.31, 95% CI [−0.40, −0.22], I 2 = 0%), whereas effectiveness was poor in those with digestive disorders, such as irritable bowel syndrome (SMD −0.37, 95% CI [−0.89, 0.16], I 2 = 74%), chronic diarrhea (SMD −0.34, 95% CI [−0.73, 0.05]), and chronic constipation (SMD −0.23, 95% CI [−0.57, 0.11], I 2 = 0%). In perinatal depressed patients, MTT was not effective (SMD 0.16, 95% CI [0.01, 0.31], I 2 = 0%). It was found that < 8 weeks (SMD −0.33, 95% CI [−0.45, −0.22], I 2 = 0%) and 8–12 weeks (SMD −0.34, 95% CI [−0.44, −0.23], I 2 = 57%) MTT were effective, while > 12 weeks (SMD 0.02, 95% CI [−0.12, 0.17], I 2 = 68%) MTT was ineffective. Conclusions Despite the overall effectiveness of MTT in treating depression and its acceptable safety profile, caution is warranted in drawing this conclusion due to limitations posed by the small sample size of included studies and heterogeneity. The efficacy of MTT for depression exhibits variation influenced by geography, patient comorbidities, and duration of administration.https://doi.org/10.1186/s12888-024-06438-zDepressionMicrobiome–targeted therapyPatient characteristicsGeographical regionPrecision medicineMeta-analysis |
| spellingShingle | Bo Pan Yiming Pan Yu-Song Huang Meng Yi Yuwei Hu Xiaoyu Lian Hui-Zhong Shi Mingwei Wang Guifen Xiang Wen-Yi Yang Zhong Liu Fangfang Xia Efficacy and safety of gut microbiome-targeted treatment in patients with depression: a systematic review and meta-analysis BMC Psychiatry Depression Microbiome–targeted therapy Patient characteristics Geographical region Precision medicine Meta-analysis |
| title | Efficacy and safety of gut microbiome-targeted treatment in patients with depression: a systematic review and meta-analysis |
| title_full | Efficacy and safety of gut microbiome-targeted treatment in patients with depression: a systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of gut microbiome-targeted treatment in patients with depression: a systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of gut microbiome-targeted treatment in patients with depression: a systematic review and meta-analysis |
| title_short | Efficacy and safety of gut microbiome-targeted treatment in patients with depression: a systematic review and meta-analysis |
| title_sort | efficacy and safety of gut microbiome targeted treatment in patients with depression a systematic review and meta analysis |
| topic | Depression Microbiome–targeted therapy Patient characteristics Geographical region Precision medicine Meta-analysis |
| url | https://doi.org/10.1186/s12888-024-06438-z |
| work_keys_str_mv | AT bopan efficacyandsafetyofgutmicrobiometargetedtreatmentinpatientswithdepressionasystematicreviewandmetaanalysis AT yimingpan efficacyandsafetyofgutmicrobiometargetedtreatmentinpatientswithdepressionasystematicreviewandmetaanalysis AT yusonghuang efficacyandsafetyofgutmicrobiometargetedtreatmentinpatientswithdepressionasystematicreviewandmetaanalysis AT mengyi efficacyandsafetyofgutmicrobiometargetedtreatmentinpatientswithdepressionasystematicreviewandmetaanalysis AT yuweihu efficacyandsafetyofgutmicrobiometargetedtreatmentinpatientswithdepressionasystematicreviewandmetaanalysis AT xiaoyulian efficacyandsafetyofgutmicrobiometargetedtreatmentinpatientswithdepressionasystematicreviewandmetaanalysis AT huizhongshi efficacyandsafetyofgutmicrobiometargetedtreatmentinpatientswithdepressionasystematicreviewandmetaanalysis AT mingweiwang efficacyandsafetyofgutmicrobiometargetedtreatmentinpatientswithdepressionasystematicreviewandmetaanalysis AT guifenxiang efficacyandsafetyofgutmicrobiometargetedtreatmentinpatientswithdepressionasystematicreviewandmetaanalysis AT wenyiyang efficacyandsafetyofgutmicrobiometargetedtreatmentinpatientswithdepressionasystematicreviewandmetaanalysis AT zhongliu efficacyandsafetyofgutmicrobiometargetedtreatmentinpatientswithdepressionasystematicreviewandmetaanalysis AT fangfangxia efficacyandsafetyofgutmicrobiometargetedtreatmentinpatientswithdepressionasystematicreviewandmetaanalysis |